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ABSTRACT
Background We evaluated the necessity of urinary 
trypsin inhibitor for patients with threatened premature 
labor.
Methods We enrolled 146 women with singleton 
pregnancies who were treated for threatened premature 
labor as inpatients. The uterine cervical length of each 
patient was ≤ 25 mm at 22–35 weeks of gestation on 
transvaginal ultrasonography. The patients were divided 
into two groups: the urinary trypsin inhibitor group (91 
patients treated with urinary trypsin inhibitor daily) 
or non-urinary trypsin inhibitor group (55 patients not 
treated with urinary trypsin inhibitor). The childbirth 
outcomes were retrospectively assessed.
Results The median cervical length measured on the 
day of admission was almost similar between the uri-
nary trypsin inhibitor and non-urinary trypsin inhibitor 
groups. Depending on the symptoms of uterine contrac-
tions, we determined whether ritodrine hydrochloride 
and/or magnesium sulfate would be appropriate for 
treatment. The median gestational week at birth was 
38 weeks in the urinary trypsin inhibitor group, and no 
obvious differences were observed when compared with 
the non-urinary trypsin inhibitor group. With regard 
to birth weight, no significant difference was found be-
tween the two groups (urinary trypsin inhibitor group, 
2776 g; non-urinary trypsin inhibitor group, 2800 g).
Conclusion Our data showed no significant beneficial 
effects of urinary trypsin inhibitor in the maternal 
course and delivery outcomes.
Key words premature labor; ulinastatin; urinary tryp-
sin inhibitor
Preterm delivery is caused by numerous pathological 
factors, and accounts for 2%–18% of all pregnancies.1, 2 
According to the 2017 Clinical Practice Guidelines of 
the Japan Society of Obstetrics and Gynecology, preg-
nant women presenting with regular cervical ripening 
(i.e., cervix dilatation or shortening of cervical length) 
at 22–36 weeks of gestation should be diagnosed with 
threatened preterm delivery.3 The preferred timing of 
cervical length measurement for the diagnosis of uterine 
cervix shortening has been considered to be 18–24 
weeks of gestation because this period is considered 
appropriate for distinguishing the lower uterine segment 
and cervix by using vaginal ultrasound.4
No evidence has shown that assessment of cervical 
length for all pregnant women would result in better 
prognosis.5 No randomized controlled trial concerning 
prevention or treatment of threatened preterm labor has 
been previously conducted in our country. Other guide-
lines for threatened preterm labor in countries besides 
Japan primarily exhibit the therapeutic efficacies of fetal 
fibronectin test, therapeutic steroids, and antibiotics 
with regard to preterm delivery.6–9
Intravaginal treatment using urinary trypsin 
inhibitor (UTI) has been reported to inhibit an increase 
in neutrophil elastase level in the uterine cervical secre-
tions of pregnant women, which is considered to cause 
preterm delivery.10, 11 However, few studies have been 
conducted concerning the effect of UTI outside Japan 
because it was only used in Japan. In addition, preven-
tive or therapeutic intervention for preterm delivery 
depends on the decision of each attending physician and 
institution on whether UTI should be used. Although 
the use of UTI for pregnant women has not been cov-
ered by health insurance in Japan, an extensive discus-
sion of the clinical efficacy and cost-effectiveness of the 
use of UTI for workforces (obstetricians, midwives, and 
pharmacists) should be necessary. Therefore, the extent 
of the effect of UTI must be objectively verified.
MATERIALS AND METHODS
We enrolled 146 women diagnosed with threatened 
preterm labor and required treatment as inpatients at 
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the Japanese Red Cross Yamaguchi Hospital between 
January 2017 and June 2018. Written informed consent 
was obtained from all participants, and the study was 
approved by the institutional review board of Japanese 
Red Cross Yamaguchi Hospital (number: H30-9). In 
patients with cervical length of < 25 mm, which was 
measured using transvaginal ultrasonography, or 
insufficient response to oral administration of ritodrine 
hydrochloride, a tocolytic drug, ritodrine hydrochloride 
was intravenously and continuously administered. 
Magnesium sulfate was additionally administered if suf-
ficient control of uterine contraction using intravenous 
ritodrine hydrochloride was not achieved. The patients 
were examined on the day of admission to exclude the 
possibility of chorioamnionitis.
The study subjects were women with singleton 
pregnancy at 22–35 weeks of gestation, traceable parto-
gram, and shortened cervical length. They were retro-
spectively divided into two groups: the (i) UTI group (91 
patients treated with UTI) and (ii) non- urinary trypsin 
inhibitor (nUTI) group (55 patients not treated with 
UTI). Delivery outcomes (gestational age at birth, birth 
weight, record of neonatal intensive care unit [NICU] 
admission, presence of preterm rupture of membrane, 
use of steroids to aid maturing of fetal lungs), change 
in cervical length during hospitalization, and length 
of hospitalization were retrospectively analyzed. We 
measured cervical length before the administration of 
UTI (ulinastatin), and the cervix was disinfected using 
povidone–iodine, followed by administration of 5000-
unit dose of UTI tablet into a portion of the vaginal 
fornix. The uterine cervical length was measured once 
weekly in the nUTI group. The Mann–Whitney U-test, 
Fisher exact test, and log-rank (Mantel–Cox) test were 
used for analysis; P < 0.05 was considered statistically 
significant.
RESULTS
The patient’s characteristics are summarized in Table 
1. The median age of the patients was 36 (range, 16–43) 
and 31 (range, 19–45) years for the UTI and nUTI 
groups, respectively. No difference was observed in 
parity between the groups (P = 0.432). The gestational 
week at the time of admission was almost similar (30 
[range, 22–35] and 31 [range, 23–35] weeks for the UTI 
and nUTI groups, respectively), and no significant dif-
ference was found between the two groups (P = 0.067).
The data in Table 2 shows that the median uterine 
cervical length on the day of admission was almost sim-
ilar in both groups (22 [range, 6–25] and 21 mm [range, 
7–25] for the UTI and nUTI groups, respectively). The 
median minimum cervical length measured during 
hospitalization was 14 (range, 0–44) and 20 (range, 
0–40) mm for the UTI and nUTI groups, respectively. 
Contrary to our expectations that UTI can continue to 
lengthen the cervix, the cervical length significantly 
shortened in the UTI group (P < 0.001). In contrast, this 
difference was not found in the nUTI group (P = 0.408) 
(Fig. 1). When similar cervical length groups were com-
pared, there was the same result between both groups at 
perinatal outcome.
The proportion of patients who were administered 
intravenous ritodrine hydrochloride was almost similar 
between the UTI and nUTI groups (UTI: 37.3%: 34/91 
Table 1. Patient's characteristics
UTI 
(n = 91)
nUTI 
(n = 55) P-value
Age (year)* 36 
(16–43)
31 
(19–45)
0.432
Parity
0 43 33
0.171
1 or more 48 22
History of threatened premature labor
Yes 18 11
> 0.99
No 73 44
Days of hospital stay* 30 
(6–121)
27 
(6–102)
0.439
Gestational weeks at admission*
30 
(22–35)
31 
(23–35)
0.067
Average number of UTI used in a patient Total 2346 units
25 
(10–106)
n.a. n.a.
*: Each value is shown as the median. The parenthesis indicated the ranges of data. Fisher exact test was used.
n.a. not applicable; nUTI, non- urinary trypsin inhibitor; UTI, urinary trypsin inhibitor.
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vs. nUTI: 29.0%: 16/55) (P = 0.362, Table 2). No sig-
nificant difference was found in the use of magnesium 
sulfate between the two groups (P = 0.426). Moreover, 
no significant difference was observed between the two 
groups regarding the mode of delivery. The proportion 
of patients who underwent cesarean section was 30.7% 
(28/91) and 30.9% (17/55) (P > 0.99) in the UTI and 
nUTI groups, respectively.
The median gestational week at birth was 37 (range, 
29–41) weeks for the UTI group, and no significant dif-
ference was found when compared with the nUTI group 
(P = 0.424) (Table 3). In cases of preterm delivery, 
chorioamnionitis was not seen during the pathological 
examinations of the placenta. The proportion of cases 
with premature rupture of membranes showed no 
significant difference between the two groups, with 
Table 2. Data of maternal course and treatment
UTI 
(n = 91)
nUTI 
(n = 55) P-value
Cervical length at 
admission (mm)*
22 
(6–25)
21 
(7–25)
0.853
Minimum cervical length(mm)* 14 
(0–44)
20 
(0–40)
< 0.001
Number of patients treated with 
Ritodrine hydrochloride
Oral 56 39
0.362
Intravenous 34 16
Number of patients treated with 
Magnesium sulfate
With 3 4
0.426
Without 88 51
Type of delivery
Vaginal 63 38
> 0.99
C-section 28 17
*: Each value is shown as the median. The parenthesis indicated the ranges of data. Fisher exact test was used.
nUTI, non- urinary trypsin inhibitor; UTI, urinary trypsin inhibitor.
Fig. 1 Comparison of cervical length between the UTI and nUTI groups on admission and mimimum length during hospitalization. The 
horizontal bars indicate the median of each group obtained by using the Mann–Whitney test. nUTI, non- urinary trypsin inhibitor; UTI, 
urinary trypsin inhibitor.
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13.1% (12/91) and 7.2% (4/55) (P = 0.412) in the UTI and 
nUTI groups, respectively, and no difference was found 
in the frequency of use of betamethasone (P = 0.556). 
The mean birth weight was 2776 (range, 1264–4194) 
and 2800 (range, 2160–3638) g for the UTI and nUTI 
groups, respectively (P = 0.979). The frequency of 
NICU admission was 31.8% (29/91) and 32.7% (18/55) 
for the UTI and nUTI groups, respectively, with no sig-
nificant difference (P > 0.99). No differences were found 
between the two groups even if only neonates hospital-
ized less than 30 weeks of gestation were examined 
(Table 4).
Figure 2 shows no significant difference between 
the two groups in the number of days from admission 
until childbirth (P = 0.081). As shown in Fig. 3, we 
assessed the course of patients from the appearance 
of threatening symptoms to hospital discharge before 
delivery by using the Kaplan–Meier method. This ex-
amination showed that patients in the nUTI group were 
discharged from the hospital earlier than those in the 
UTI group (P = 0.009).
Table 3. Data at delivery and childbirth outcomes
UTI 
(n = 91)
nUTI 
(n = 55) P-value
Gestational weeks at birth*
37 
(29–41)
38 
(34–40)
0.424
Premature rupture of membrane
Yes 12 4
0.412
No 79 51
Number of patients treated with  
Betamethasone
With 1 2
0.556
Without 90 53
Birth weight (g)* 2776 
(1264–4194)
2800 
(2160–3638)
0.979
Admission to NICU
Yes 29 (20) 18 (13)
> 0.99
No 62 37
Blood loss at delivery (g)* 350 
(65–4330)
442 
(91–1985)
0.081
*: Each value is shown as the median. The parenthesis indicated the ranges of data. Fisher exact test was used.
NICU, neonatal intensive care unit; nUTI, non- urinary trypsin inhibitor; UTI, urinary trypsin inhibitor.
Table 4. Patients on admission before 30 gestational weeks
UTI 
(n = 41)
nUTI 
(n = 21) P-value
Gestational weeks at birth*
37 
(32–41)
38 
(34–40)
0.116
Premature rupture of membrane
Yes 4 2
> 0.99
No 37 19
Type of delivery
Vaginal 28 15
0.771
C-section 13 6
Birth weight (g)* 2708 
(1878–4194)
2966 
(2326–3638)
0.116
Admission to NICU
Yes 14 (10) 8 (2)
0.785
No 27 13
Blood loss at delivery (g)* 252 
(65–1680)
479 
(223–1985)
0.399
*: Each value is shown as the median. The parenthesis indicated the ranges of data. Fisher exact test was used.
NICU, neonatal intensive care unit; nUTI, non- urinary trypsin inhibitor; UTI, urinary trypsin inhibitor.
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DISCUSSION
We enrolled 146 cases for hospitalization on the condi-
tions that cervical length was < 25 mm during 22–35 
weeks of gestation, and retrospectively examined 
whether the administration of UTI resulted in differenc-
es in delivery outcomes. No significant differences were 
observed between the nUTI and UTI groups in terms of 
gestational age at birth, birth weight, and hospitalization 
in the NICU.
Several crucial molecules [prostaglandin (PG) E2, 
PGF2α, and oxytocin], their receptors, and expression 
of their degrading enzymes are involved in uterine 
contraction.12, 13 PGE2 and PGF2α are produced from 
the decidua, amnion, and myometrial cells, and proin-
flammatory cytokines, such as IL1β, are closely related 
to the production of these molecules. For instance, 
microbial infections or non-specific inflammatory re-
sponses trigger the production of IL-1β by microphages, 
facilitating the production of PGs. The production of 
IL-8 by macrophages or endocervical cells induces 
neutrophil migration; elastase is then released from 
these neutrophils, causing the collagen to dissolve, 
thereby promoting cervical ripening. Moreover, IL-8 
facilitates the production and release of the endogenous 
collagen-degrading enzyme matrix metalloproteinase 
(MMP), thereby promoting cervical ripening. Recently, 
chorioamnionitis has been considered to be caused by 
the microbiome in the amniotic fluid.14 In this study, we 
also examined all patients who delivered preterm for the 
presence of clinical chorioamnionitis, and pathological 
chorioamnionitis was not found in their placentas.
A large-scale observational study in the Japanese 
population showed that the cervical length in women at 
20–24 weeks of gestation was 42.2 ± 8.5 mm (primi-
gravida: 42.5 ± 8.4 mm; multi-gravida: 38.4 ± 9.6 mm), 
and that 41.7% and 75.0% of women with cervical 
length of < 25 mm and < 20 mm, respectively, resulted 
in preterm delivery.15 Based on this finding, we con-
sidered women with cervical length of < 25 mm at the 
hospital as patients with threatened preterm labor. The 
cervical length changed daily during hospitalization.
The present study suggests that the administration 
of UTI does not contribute to the improvement of cervi-
cal length. However, there was a limitation regarding 
this issue. We examined the cervical length daily at 
administering UTI and once weekly in the UTI and 
nUTI groups, respectively. We should consider the pos-
sibility that the frequencies of measurement for cervical 
length were not the same between the two groups, 
while indicating that the environment in the vagina may 
be possibly disrupted by iodine disinfection and UTI 
administration. In addition, the patient cannot be easily 
discharged because the length of the cervix shortens, 
and the hospitalization period is extended.
Although we did not assess the presence of neutro-
phil elastase in cervical mucus, it has been described to 
be efficacious in the prediction of preterm delivery.16, 17 
Another study showed a correlation between cervical 
length and prognosis in 54 patients with twin pregnan-
cies, and the combination of assessment of cervical 
length and neutrophil elastase was particularly useful.18 
In addition, pregnant women considered positive for 
Fig. 2. Comparison of the periods between the UTI and nUTI 
groups from admission to delivery. Data are represented by box-
and-whisker plots. The lines inside boxes indicate median value, 
and the upper and lower limits of the boxes and whiskers indicate 
the interquartile and total ranges. nUTI, non- urinary trypsin 
inhibitor; UTI, urinary trypsin inhibitor.
Fig. 3. Courses of patients from admission due to appearance of 
threatening symptoms until the transient hospital discharge before 
delivery. nUTI, non- urinary trypsin inhibitor; UTI, urinary 
trypsin inhibitor.
209
Evaluation of UTI in threatened preterm delivery
© 2019 Tottori University Medical Press
fetal fibronectin in cervical secretions have been report-
ed to have a high risk of preterm delivery.6, 19 However, 
the specimens for detecting the fetal fibronectin were 
not collected in this study. If we had examined factors, 
such as fibronectin and neutrophil elastase in addition to 
cervical length, we would have obtained more solid data 
to resolve this issue.
The management of threatened preterm labor was 
different in Japan and other countries, particularly in 
western countries. In western countries, based on the 
evidence that the effect of tocolysis with tocolytic agents 
lasts only for <48 h, short-term tocolysis is generally 
performed by the administration of steroids for fetal 
lung maturity and intravenous oxytocic agent within 
48 h until the onset of effect.20 Conversely, ritodrine 
hydrochloride for long-term tocolysis is generally used 
in Japan.21 The results of this study indicated the pos-
sibility that using UTI could prolong hospital admission. 
Several adverse effects associated with ritodrine hydro-
chloride, such as hepatic dysfunction, rhabdomyolysis, 
and pulmonary edema have been reported. Therefore, 
long-term use of ritodrine hydrochloride should be pre-
scribed under strict observation. No obvious differences 
were observed in delivery outcomes even when the use 
of ritodrine hydrochloride was restricted within 48 h, 
leading to the diminished use of drugs.21
This study has some limitations. First, our study 
is a single-center retrospective study, and because our 
hospital is a secondary perinatal center, we primarily 
deal with relatively low-risk cases. In the future, a 
multi-center joint study should be conducted to examine 
the efficacy of UTI, including high-risk cases with poor 
prognosis. Second, ritodrine hydrochloride was used 
for all patients, and long-term tocolysis was performed; 
however, the effects and use of ritodrine hydrochloride 
were not studied in detail. The usefulness of long-term 
administration of other tocolytic agents, except for UTI, 
must be reconsidered. Third, our study did not mention 
the cost of treatment, hours on duty of obstetricians and 
midwives, and efforts of pharmacists for pharmaceutical 
preparation. However, we cannot waste the effort to cre-
ate 2346 vaginal tablets or labor force to insert vaginal 
tablets after washing the vagina. We speculate that 
adaptation as a medication should be considered well if 
there is no effect far beyond great efforts.
The administration of UTI in patients with 
threatened preterm delivery did not induce beneficial 
effects in delivery outcomes, suggesting the prospect of 
avoiding daily vaginal washing and UTI administration 
during their hospitalization, while keeping patients at 
rest and administering tocolytic agents.
The authors declare no conflict of interest.
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